On Friday, RegenoCELL Therapeutics, Inc. announced they are planning to open another facility in Panama. The facility’s purpose will be to treat patients for congestive heart failure and peripheral artery disease with the Company’s autologous stem cell therapy.
The RegenoCELL adult stem cell treatment can be used to treat peripheral artery disease. In the United States, there are over 10 million people suffering from the lack of sufficient blood flow to the extremities with an equal number in Europe. Diabetics most often experience this disease in their toes and lower legs.
Since 2005, RegenoCELL’s stem cell therapy has successfully treated more than 500 patients. The typical patient is suffering from congestive heart failure with no treatment options and three to six months to live. Over 5 years later patients initially treated are leading active and fulfilling lives. Less than a half liter of blood undergoes extraction from the patient and is sent to RegenoCELL’s subsidiary cell processing facility in Israel. There, the patient’s stem cells are extracted and grown from tens of thousands into many millions.
The stem cells are primed for angiogenesis or blood vessel formation. The patient subsequently travels to a jurisdiction where they permit autologous therapy. The patient has the stem cells transplanted in a hospital in a catheterization laboratory in a procedure similar to angioplasty.
RegenoCELL Therapeutics, Inc.’s treatment for congestive heart failure when cleared for importation into Panama will undergo administration at the Hospital Sante Fe. Panama is a convenient location for patients living in the United States, Central and South America. When the treatment is cleared for importation, it will offer patients an additional location where RegenoCELL’s autologous stem cell treatments will be permitted.
Headquartered in Natick, Massachusetts, RegenoCELL Therapeutics, Inc. is a stem cell therapy company using adult stem cells for autologous treatment of patients. The Company plans to obtain regulatory approval in the U.S. and the European Community to market their stem cell treatments. Via their wholly owned foreign subsidiaries, they are marketing their stem cell treatments for transplantation in jurisdictions where autologous therapy is permitted.
For more information visit: www.regenocell.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment